Nektar Therapeutics (NASDAQ:NKTR – Get Free Report)‘s stock had its “market perform” rating reissued by analysts at William ...

Fintel reports that on March 14, 2025, Oppenheimer upgraded their outlook for Nektar Therapeutics (NasdaqCM:NKTR) from ...

Nektar Therapeutics (NKTR) stock surges as Oppenheimer upgrades ahead of key mid-stage trial readout for an eczema drug. Read ...

Shuttle Pharmaceuticals SHPH stock declined by 25.6% to $0.32 during Friday's pre-market session. The company's market cap stands at $1.5 million. AirSculpt Technologies AIRS shares decreased by 16.33 ...

Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

Nektar (NKTR) delivered earnings and revenue surprises of -15.38% and 25.23%, respectively, for the quarter ended December ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report), with a ...

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash ...

William Blair analyst Andy Hsieh reiterated a Hold rating on Nektar Therapeutics (NKTR – Research Report) today. The company’s shares closed ...

Despite a net loss, Nektar Therapeutics (NKTR) showcases promising developments in its autoimmune pipeline and maintains a ...

The San Francisco-based company said it had net income of 3 cents per share. Earnings, adjusted for non-recurring costs, came to 15 cents per share. The results topped Wall Street expectations. The ...

Shares of Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) have earned a consensus rating of “Buy” from the six analysts ...